HC Wainwright Issues Negative Forecast for Rezolute Earnings

Rezolute, Inc. (NASDAQ:RZLT) – HC Wainwright cut their FY2030 EPS estimates for Rezolute in a research report issued on Friday, November 7th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $0.49 per share for the year, down from their previous estimate of $0.61. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share.

Rezolute (NASDAQ:RZLT) last released its earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.09.

Several other analysts have also issued reports on RZLT. BTIG Research reissued a “buy” rating and issued a $17.00 price target on shares of Rezolute in a research report on Thursday, September 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Wednesday, October 8th. JMP Securities set a $17.00 target price on Rezolute in a research report on Wednesday, October 29th. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Rezolute in a report on Thursday, September 18th. Finally, Citigroup reiterated an “outperform” rating on shares of Rezolute in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Rezolute Stock Up 0.9%

NASDAQ RZLT opened at $10.04 on Monday. The company has a market cap of $931.01 million, a PE ratio of -10.80 and a beta of 0.07. Rezolute has a 52 week low of $2.21 and a 52 week high of $11.46. The firm’s 50-day simple moving average is $8.78 and its two-hundred day simple moving average is $6.33.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Rezolute in the second quarter worth $25,000. Ameritas Investment Partners Inc. bought a new position in Rezolute in the 2nd quarter worth about $30,000. Legal & General Group Plc purchased a new stake in shares of Rezolute in the 2nd quarter valued at about $32,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Rezolute in the 3rd quarter valued at about $94,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Rezolute during the 2nd quarter valued at about $46,000. Institutional investors own 82.97% of the company’s stock.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.